What to try for knee soreness before a bigger decision

What to try at home first

A stiff knee doesn't always need full rest. Try short walks, gentle leg exercises, and less time on steep ground while the flare settles.

A cane or brace may make walking steadier. Topical medicine means knee cream or gel; before using it, let a pharmacist compare it with your other drugs.

What to ask about non-surgical care

Cortisone may ease soreness for a short time. Gel means hyaluronic acid put into the knee to add lubrication, yet it doesn't help everyone.

PRP, or platelet-rich plasma, starts with a sample of your blood. Spinning separates the layers, and a needle carries the part with more platelets back to the joint.

Studies don't agree on PRP. Some found less pain or easier walking, while a careful trial found no added benefit over saline in the knee.

QC Kinetix in Chandler calls its blood-based procedures biologic therapies. Clinic staff can explain the risks and whether these knee surgery alternatives fit your exam.

When to talk about surgery

Surgery may come up when other care hasn't eased severe soreness or poor movement. The exam, X-ray, health, and daily limits guide that talk.

A knee locked after a major injury needs prompt care and may require a different procedure. With slow wear, ask whether another non-surgical choice still makes sense.

What to weigh before replacement

Knee replacement can help when severe damage makes daily life hard. It also means an operation, recovery time, and risks that require a careful talk.

Ask how each choice may change walking, sleep, stairs, and time with family. Don't decide until you understand both the likely relief and the work of recovery.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing, topical NSAIDs, oral NSAIDs and intra-articular glucocorticoid injections in knee OA; radiofrequency ablation for knee OA is only a conditional recommendation.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA; topical NSAIDs are strongly recommended (Level 1A); oral and transdermal opioids are strongly NOT recommended (Level 5).

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. High-quality evidence from 44 trials (3,537 participants) shows land-based exercise reduced knee OA pain by an equivalent of 12 points on a 0-100 scale (SMD -0.49) immediately after treatment, with moderate-quality evidence for a ~10-point function gain; the effect attenuated but persisted at 2-6 months (SMD -0.24). No serious adverse events were reported in any included trial.

   Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. — Exercise for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2015. DOI: 10.1002/14651858.CD004376.pub3.

4. A Bayesian network meta-analysis restricted to LARGE randomized trials (>=100 patients per group) of 18 intra-articular interventions in knee and hip OA found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had NO effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86) than placebo. Effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo.

   da Costa BR, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

5. In a 2-year, double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, intra-articular triamcinolone 40 mg every 12 weeks caused significantly GREATER cartilage volume loss than saline (index-compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with NO significant difference in pain (-1.2 vs -1.9 on the WOMAC Likert pain subscale).

   McAlindon TE, LaValley MP, Harvey WF, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

6. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.'

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

7. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-poor and leukocyte-rich PRP significantly improved 6-12 month WOMAC function versus placebo (MD -10.54 and -13.20 respectively) and both were superior to hyaluronic acid, with leukocyte-poor PRP ranked first (P-score 0.96) — a materially more favourable read of PRP than the RESTORE trial, which is why this corpus presents both.

   Journal of Orthopaedic Surgery and Research authors — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.

8. FDA states verbatim: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production. There are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

9. A safety review of intra-articular PRP in knee OA found significantly higher rates of mild knee pain and swelling than hyaluronic acid (p<0.001), driven specifically by leukocyte-RICH formulations; leukocyte-poor PRP showed a safety profile similar to HA. No severe adverse events were reported in any group.

   PM&R authors — Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared with hyaluronic acid and saline in knee osteoarthritis.. PM&R, 2026. DOI: 10.1002/pmrj.70141.

10. In a double-blind, sham-controlled trial of 146 patients aged 35-65 with a degenerative medial meniscus tear and NO knee osteoarthritis, arthroscopic partial meniscectomy produced no significant benefit over sham surgery on any primary outcome at 12 months (Lysholm 21.7 vs 23.3 points; WOMET 24.6 vs 27.1; pain after exercise 3.1 vs 3.3).

    Sihvonen R, Paavola M, Malmivaara A, et al. — Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear.. New England Journal of Medicine, 2013. DOI: 10.1056/NEJMoa1305189.

11. In a placebo-surgery-controlled trial of 180 patients with knee OA, neither arthroscopic debridement nor arthroscopic lavage outperformed placebo surgery at ANY time point over 24 months on any of five self-reported pain/function scales or an objective walking and stair-climbing test.

    Moseley JB, O'Malley K, Petersen NJ, et al. — A controlled trial of arthroscopic surgery for osteoarthritis of the knee.. New England Journal of Medicine, 2002. DOI: 10.1056/NEJMoa013259.

12. A prospective longitudinal study of 64 patients with acute medial meniscus posterior root tear managed non-operatively found 76.6% continued non-operative care and only 23.4% converted to surgery (median 6 months). Pain fell from 7.6 to 1.3 on an 11-point scale within 6 months and stayed there — even though structural degeneration on MRI progressed. Symptoms and structure moved in opposite directions.

    Knee Surgery, Sports Traumatology, Arthroscopy authors — Clinical improvement despite structural degeneration after nonoperative treatment of medial meniscus posterior root tear: A prospective longitudinal study.. Knee Surgery, Sports Traumatology, Arthroscopy, 2026. DOI: 10.1002/ksa.70570.

13. In a randomized trial of 100 patients with moderate-to-severe knee OA eligible for total knee replacement, TKR followed by 12 weeks of non-surgical care improved the KOOS4 score more than the same non-surgical programme alone (32.5 vs 16.0 points; adjusted mean difference 15.8, 95% CI 10.0 to 21.5) — but produced four times as many serious adverse events (24 vs 6, P=0.005), and 26% of the non-surgical group had chosen surgery within 12 months, meaning roughly three-quarters had not.

    Skou ST, Roos EM, Laursen MB, et al. — A Randomized, Controlled Trial of Total Knee Replacement.. New England Journal of Medicine, 2015. DOI: 10.1056/NEJMoa1505467.